"VBI Vaccines" from_date:2012

authors:Jeannette L. Comeau MD MSc, Dorothy L. Moore MD, Michelle A. Barton MD Potential Conflict of InterestDr Jeannette Comeau reported acting as a co-investigator on vaccine clinical trials (no direct financial compensation) for: GlaxoSmithKline Inc, ModernaTX Inc, Merck & Co. Inc, Sanofi Pasteur Inc, VBI Vaccines Inc, Pfizer, Medical R&D Inc, MedImmune LLC, and Janssen Research & Developement LLC. No other

Interest: VBI vaccines; Scientific Advisory Board: Compass Therapeutics, Zumutor Biologics Inc, Tizona Therapeutics; MBA: Advisory Board: Bristol-Myers Squibb, Merck, Novartis, Arrowhead, Pfizer, Galactone, Werewolf, Fathom; Consultant: Bristol-Myers Squibb, Novartis, Genetch-Roche, Exelixis, Eisai, Aveo, Array, AstraZeneca, Idera, Aduro, ImmunoCore, Boehringer-Ingelheim, Lion, Newlink, Surface, Alexion

according to a web-based permuted blocked randomisation. Participants received either TAV or MAV which were administered as an intramuscular dose (1 mL) of TAV (10 μg; Sci-B-Vac, VBI Vaccines [SciVac, Rehovot, Israel]) or MAV (20 μg; Engerix-B [GlaxoSmithKline Biologicals, Rixensart, Belgium]) on days 0, 28, and 168 with six study visits and 24 weeks of follow-up after the third vaccination. Participants , the safety profile of TAV was similar to that of MAV. The safety and efficacy of TAV shows its usefulness for the prevention of HBV infection in adults, including those with stable and controlled chronic conditions. VBI Vaccines.

reports of PREHEVBRIO® vaccine exposure within 28 days prior to conception or at any time during pregnancy and delivery, as well as maternal, obstetrical, pregnancy, fetal and neonatal outcomes. This registry is primarily descriptive and designed to detect potential safety signals rather than test hypotheses. VBI Vaccines was granted a Biologic License by the FDA on 30 November 2021, to introduce

opinion, recommending the granting of a marketing authorization for the medicinal product PreHevbri, intended for the active immunization against hepatitis B virus infection (HBV).[65] The applicant for this medicinal product is VBI Vaccines B.V.[65]Brand names[edit]The common brands available are Recombivax HB (Merck),[5] Engerix-B (GSK),[6] Elovac B (Human Biologicals Institute, a division of Indian

. ClinicalTrials.gov Identifier: NCT03393754 Recruitment Status : Completed First Posted : January 8, 2018 Results First Posted : July 7, 2020 Last Update Posted : July 17, 2020 Sponsor: VBI Vaccines Inc. Information provided by (Responsible Party): VBI Vaccines Inc. * Study Details * Tabular View * Study Results Tampere, Finland Turku Vaccine Research Clinic Turku, Finland Sponsors and Collaborators VBI Vaccines Inc. Investigators Study Director: Francisco Diaz-Mitoma, MD, PhD VBI Vaccines Study Documents (Full-Text) Documents provided by VBI Vaccines Inc.: Study Protocol[PDF] July 17, 2017 Statistical

Recruitment Status : Completed First Posted : January 24, 2018 Results First Posted : October 14, 2020 Last Update Posted : March 25, 2021 Sponsor: VBI Vaccines Inc. Information provided by (Responsible Party): VBI Vaccines Inc. * Study Details * Tabular View * Study Results * Disclaimer * How to Read a Study RecordStudy DescriptionGo to Top of Page Study Description Study Design Arms and Interventions St. George's University Hospital NHS Foundation Trust London, United Kingdom Southampton General Hospital Southampton, United Kingdom Sponsors and Collaborators VBI Vaccines Inc. Investigators Study Director: Francisco Diaz-Mitoma, MD, PhD VBI Vaccines Study Documents (Full-Text) Documents

not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. ClinicalTrials.gov Identifier: NCT03382977 Recruitment Status : Active, not recruiting First Posted : December 26, 2017 Last Update Posted : July 1, 2022 Sponsor: VBI Vaccines Inc. Information provided by (Responsible Party): VBI States, New York The Neurological Institute of New York Columbia University Medical Center New York, New York, United States, 10032 Sponsors and Collaborators VBI Vaccines Inc. Investigators Study Director: Francisco Diaz-Mitoma, MD Variation Biotechnologies Inc. More InformationGo to Top of Page

Vaccines Inc. Collaborator: Clinical Trial Data Services, LLC Information provided by (Responsible Party): VBI Vaccines Inc. * Study Details * Tabular View * Study Results * Disclaimer * How to Read a Study RecordStudy DescriptionGo to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Brief Summary: The purpose Centre Halifax, Nova Scotia, Canada, B3K 6R8 Canada, Quebec McGill University Health Centre - Vaccine Study Pierrefonds, Quebec, Canada, H9H 4Y6 Sponsors and Collaborators VBI Vaccines Inc. Clinical Trial Data Services, LLC Investigators Principal Investigator: Joanne Langley, MD IWK Health Centre More